Double-blind Crossover Study With Physostigmine in Patients With Degenerative Cerebellar Diseases

Wessel, K.; Langenberger, Karsten; Nitschke, M. F.; Kömpf, Detlef

doi:10.1001/archneur.1997.00550160041013

Cited by 30 publications

(18 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of these studies were negative or not conclusive due to limitations such as lack of randomization and of a placebo group, non-validated outcomes, multiple primary endpoints, inclusion of different types of cerebellar ataxia, and short periods of follow-up. Physostigmine [70], fluoxetine [71], tandospirone [72], lamotrigine [73], buspirone [74] and IGF-1 [75] are examples of the evaluated drugs with negative or non-conclusive results. None of these drugs can be recommended for the treatment of SCA3/MJD.…”

Section: Treatmentmentioning

confidence: 99%

Machado Joseph disease: clinical and genetic aspects, and current treatment

Saute

Jardim

2015

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

Section: Treatmentmentioning

confidence: 99%

Machado Joseph disease: clinical and genetic aspects, and current treatment

Saute

Jardim

2015

Expert Opinion on Orphan Drugs

View full text Add to dashboard Cite

“…Adverse effects may limit treatment. Physostigmine has no significant effect on cerebellar tremor [162, 163]. …”

Section: Ataxia and Tremormentioning

confidence: 99%

Symptomatic Treatment of Multiple Sclerosis

2006

View full text Add to dashboard Cite

Besides immunomodulation and immunosuppression, the specific treatment of symptoms is an essential component of the overall management of multiple sclerosis (MS). Symptomatic treatment is aimed at the elimination or reduction of symptoms impairing the functional abilities and quality of life of the affected patients. Moreover, with symptomatic treatment the development of a secondary physical impairment due to an existing one may be avoided. Many therapeutic techniques as well as different drugs are used for the treatment of MS symptoms, but only a few of them have been investigated, especially in MS patients, and are approved by the national health authorities. Despite an overwhelming number of publications, only a few evidence-based studies exist and consensus reports are very rare, too. Therefore, it seemed necessary to develop a consensus statement on symptomatic treatment of MS comprising existing evidence-based literature as well as therapeutic experience of neurologists who have dealt with these problems over a long time. This consensus paper contains proposals for the treatment of the most common MS symptoms: disorders of motor function and coordination, of cranial nerve function, of autonomic, cognitive, and psychological functions as well as MS-related pain syndromes and epileptic seizures.

show abstract

“…The authors of both articles concluded that physostigmine was not effective in the treatment of this disease (13,53).…”

Section: Cortical Cerebellar Atrophiesmentioning

confidence: 99%

“…As previously mentioned, the results of trials with L-hydroxytryptophan (40,94), physostigmine (53), TRH (52), vigabatrin (91), riluzole (102) and buspirone (92), in groups that included patients with several types of ataxia, did not permit individualization of the effect of these drugs on FRDA.…”

Section: Spinocerebellar Atrophiesmentioning

confidence: 99%